STOCK TITAN

Theravance Biopharma Inc - TBPH STOCK NEWS

Welcome to our dedicated news page for Theravance Biopharma (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theravance Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theravance Biopharma's position in the market.

Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive results from the YUPELRI Phase III clinical trial in China, demonstrating efficacy and safety for COPD patients. Top-line results show a statistically significant increase in trough FEV1 versus placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Theravance Biopharma (TBPH) reports record high net sales of $58.3 million for YUPELRI in Q3 2023, with a 9% increase from Q3 2022. The company expects to complete a $325 million capital return program by year-end, having returned $30.8 million via share repurchases during Q3 2023 and $294.6 million since inception through quarter end. The Q3 2023 GAAP Net Loss was $9.0 million and Non-GAAP Loss was $0.7 million. Áine Miller, Ph.D. has been promoted to SVP of Development, while Richard A. Graham, Ph.D. will remain through February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
-
Rhea-AI Summary
Theravance Biopharma to report Q3 2023 financial results and provide business update on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences earnings
Rhea-AI Summary
Theravance Biopharma announces positive ampreloxetine data in neurogenic orthostatic hypotension (nOH) at MDS Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
-
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) to Report Q2 2023 Financial Results and Business Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
management
Theravance Biopharma Inc

Nasdaq:TBPH

TBPH Rankings

TBPH Stock Data

466.66M
15.86M
14.51%
103.35%
15.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Cayman Islands
George Town

About TBPH

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.